Lung Cancer Genomic Testing Market - A Global and Regional Analysis: Focus on Product, Technology, Panel Type, Sample Type, and End User - Analysis and Forecast, 2021-2031

Report
244 Pages
May 2022
Region: Global
BIS Research
ID: 5596055

Global Lung Cancer Genomic Testing Market to Reach $3,279.8 Million by 2031

The lung cancer genomic testing medicine market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031. The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.

Market Lifecycle Stage

The global lung cancer genomic testing market is still in the nascent phase. Various companies are increasing investments in research and development to facilitate the development of lung cancer genomic testing, which is expected to further increase the adoption of lung cancer genomic tests.

The shift of healthcare systems toward precision diagnostic and precision medicine will drive the adoption of lung cancer genomic testing facilitating informed treatment decision making and improving healthcare outcomes. Increasing recommendations by the international oncology societies for the use of genomic testing for lung cancer diagnosis provides major opportunities in the global lung cancer genomic testing market.

Impact

The presence of major in-vitro diagnostics (IVD) product providers of lung cancer genomic tests in regions such as North America and Europe has a major impact on the market. For instance, Qiagen provides therascreen Solid Tumor assays, a real-time polymerase chain reaction (PCR) test for EGFR detection in non-small cell lung cancer (NSCLC) patients. Additionally, Roche provides Cobas EGFR Mutation Test, a PCR-based test, and FoundationOne CDx by Foundation Medicine Inc., which is a next-generation sequencing (NGS) based assay for NSCLC.
The presence of major laboratory developed tests (LDTs) service providers companies offer lung cancer genomic testing in regions such as North America and Europe, which has a major impact on the market. The LDTs are offered by Quest Diagnostics and Laboratory Corporation of America (Labcorp), targeting various lung cancer genes, for example, EGFR, MET, ALK, and ROS, based on Fluorescence in situ Hybridization (FISH) and NGS. The presence of these companies has a positive impact on market growth.

Impact of COVID-19

The global lung cancer genomic testing market is dominated by the utility in diagnostic laboratories, hospitals, and clinics. During the beginning of the COVID-19 pandemic, multiple countries witnessed a complete or a partial lockdown, and all elective surgeries and procedures were halted in the healthcare settings. Since the lung cancer genomic testing is categorized under the elective procedure, the impact of the COVID-19 pandemic on the lung cancer genomic testing was negative. BIS Research analysis has concluded that the market witnessed a drop of 3.24% in the annual growth rate of global lung cancer genomic testing market.

Market Segmentation

by Product Type (Products, Services)

The global lung cancer genomic testing market services segment is expected to be dominated. This is owing to the easy availability, accessibility, and adaptation of LDTs, due to lower cost when compared with the product's market consisting of IVD.

by Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization, Others)

The global lung cancer genomic testing market by polymerase chain reaction (PCR) is expected to be dominated. This is owing to the overall cost efficiency and high sensitivity of the PCR-based genomic test for the detection of disease-causing mutations in lung cancer.

by Sample Type (Tissue Biopsy, Liquid Biopsy)

The global lung cancer genomic testing market by tissue biopsy sample type is expected to be dominated. This is owing to the standard healthcare practice of extracting a lung tissue biopsy for lung cancer diagnosis, which is further utilized for lung cancer genomic testing.

by Panel Type (Multi-Gene Panel, Single-Gene Panel)

The global lung cancer genomic testing market by multi-gene panel type is expected to be dominated. This is owing to the standard healthcare practice and familiarity of healthcare professionals with the extraction of lung tissue biopsy for lung cancer diagnosis, which is further utilized for lung cancer genomic testing.

by End User (Research Organization, Hospitals/Clinics, Diagnostic Laboratories, Other End Users)

The global lung cancer genomic testing market by research organization end user is expected to be dominated. This is owing to a large number of clinical research and academic organizations where lung cancer genomic testing is utilized for drug development, development of companion diagnostics, and enrolment of patients in clinical trials.

by Region

North America - U.S. and Canada
Latin America - Brazil, Mexico, and Rest-of-Latin America
Europe - U.K., Germany, Italy, Spain, France, and Rest-of-Europe
Asia-Pacific - Japan, China, South Korea, Singapore, Australia, India, and Rest-of-Asia-Pacific
Rest-of-the-World

The global lung cancer genomic testing market is expected to be dominated by North America, generating the highest revenue of $713.5 million. This is owing to the presence of a large number of research organizations and products and services companies in the U.S.

Recent Developments in Global Lung Cancer Genomic Testing Market

In December 2021, FDA approved Thermo Fisher Scientific’s NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue Oncomine Dx Target Test, now approved for 12 NSCLC targeted therapies globally.
In September 2021, FDA approved Thermo Fisher Scientific’s tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations- Oncomine Dx Target Test now approved as CDx for five targeted NSCLC therapies in the U.S.
In September 2020, Laboratory Corporation of America Holdings entered into a commercial partnership with Resolution Bioscience; the company rolled out Resolution ctDx lung liquid biopsy test.
In May 2021, Qiagen launched the first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumors and expanded precision medicine options in lung cancer.
In January 2020, Qiagen built a global collaboration with Amgen for companion diagnostic development in non-small cell lung cancer.

Demand – Drivers and Limitations

Following are the demand drivers for the global lung cancer genomics market:

High Lung Cancer Mortality Rate
Advancements in the Next-Generation Technologies for Genomic Testing
Increasing Number of Targeted Therapies
Decreasing Cost of Genetic Testing Globally

The market is expected to face some limitations too due to the following challenges:

Uncertain Regulatory Scenario for Genomic Testing
Lack of Viable Tissue Biopsy Sample
Uneven Reimbursement Scenario for Genomic Testing

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The product segment helps the reader understand the different types of products, i.e., products (in-vitro diagnostic test) and services (laboratory developed tests) with respect to lung cancer genomic testing. Additionally, the study provides the reader a detailed understanding of the segmentation of the product and market analysis by technology, sample type, panel type, and understand the growth potential of the market by utilization based on the different end users.

Growth/Marketing Strategy: The global lung cancer genomic testing market has seen major development by key players operating in the market, such as product launches, synergistic activities, mergers and acquisitions, business expansion, partnership, collaboration, joint venture, and funding. The favored strategy for the companies has been synergistic activities and mergers and acquisitions, strengthening the product portfolio and their position in the lung cancer genomic testing market. For instance, in February 2022, Foundation Medicine Inc. announced its collaboration with Eli Lilly and Company to develop FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics for RETEVMO, which was FDA approved in May for non-small cell lung cancer patients.

Competitive Strategy: Key players in the global lung cancer genomic testing market analyzed and profiled in the study involve the product manufacturer and test service providers. Moreover, a detailed competitive benchmarking of the players operating in the global lung cancer genomic testing market has been done to help the readers understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, key developments, and market penetration.

Some of the prominent names established in this market are:

QIAGEN N.V.
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
CENTOGENE N.V.
BGI
CeGaT GmbH
Illumina, Inc.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
CD Genomics
NeoGenomics Laboratories
Admera Health
OncoDNA
OPKO Health, Inc.
Invitae Corporation
Veracyte, Inc.

Companies that are not a part of the above-mentioned pool have been well represented across different sections of the report (wherever applicable).

1 Markets

1.1 Product Definition
1.1.1 Lung Cancer Genomic Testing
1.1.2 Inclusion and Exclusion
1.1.3 Market Scope
1.1.3.1 Key Questions Answered by this Report:
1.2 Research Methodology
1.2.1 Primary Data Sources
1.2.2 Secondary Data Sources
1.3 Market Estimation Model
1.4 Criteria for Company Profiling

2 Market Overview

2.1 Introduction
2.2 Global Prevalence of Lung Cancer
2.3 Significance of Genomic Testing in Lung Cancer
2.4 COVID-19 Impact on Lung Cancer Genomic Testing Market
2.4.1 Disruption in Global Lung Cancer Genomic Testing Market: Pre- and Post-COVID-19 Market Analysis
2.4.2 COVID-19 Affecting Supply Chain of Global Lung Cancer Genomic Testing Market
2.4.3 Interruption in Research and Clinical Development and Commercial Operation
2.4.4 Navigating Crisis Recovery and Looking to the Future

3 Industry Analysis

3.1 Global Legal Requirements and Regulations
3.1.1 Legal Requirements and Frameworks in the U.S.
3.1.1.1 Centers for Medicare & Medicaid Services Regulation
3.1.2 Legal Requirements and Frameworks in Europe
3.1.3 Legal Requirements and Frameworks in Asia-Pacific
3.1.3.1 China
3.1.3.2 Japan
3.1.4 Latin America (Brazil and Mexico)
3.2 Patent Landscape
3.2.1 Patent Filing Trend
3.2.2 Patent Analysis by Country
3.2.3 Patent Analysis by Technology

4 Market Dynamics

4.1 Overview
4.2 Impact Analysis
4.3 Market Driving Factors
4.3.1 High Lung Cancer Mortality Rate
4.3.2 Advancements in the Next-Generation Technologies for Genomic Testing
4.3.3 Increasing Number of Targeted Therapies
4.3.4 Decreasing Cost of Genetic Testing Globally
4.4 Market Restraining Factors
4.4.1 Uncertain Regulatory Scenario for Genomic Testing
4.4.2 Lack of Viable Tissue Biopsy Sample
4.4.3 Uneven Reimbursement Scenario for Genomic Testing
4.5 Market Opportunities
4.5.1 Improving Global Recommendations for Lung Cancer Genomic Testing
4.5.1.1 American Society of Clinical Oncology (ASCO) Recommendations
4.5.1.2 European Society of Clinical Oncology (ESMO) Recommendations
4.5.1.3 Pan-Asia Clinical Practical Guidelines
4.5.2 Rising Investment in Research and Development
4.5.3 Emerging Economies

5 Competitive Landscape

5.1 Key Strategies and Developments
5.1.1 Synergistic Activities
5.1.2 Regulatory Approvals
5.1.3 Product Launches and Upgradations
5.1.4 Mergers and Acquisitions
5.1.5 Business Expansion
5.1.6 Investment, Funding, and Joint Venture
5.1.7 Market Share Analysis by Company
5.1.8 Growth-Share Analysis by Company

6 Global Lung Cancer Genomic Testing Market, (by Product Type), $Million, 2020-2031

6.1 Overview
6.1.1 Products
6.1.2 Services

7 Global Lung Cancer Genomic Testing Market, (by Technology), $Million, 2020-2031

7.1 Overview
7.2 Next-Generation Sequencing
7.3 Polymerase Chain Reaction (PCR)
7.4 Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)
7.5 Others

8 Global Lung Cancer Genomic Testing Market, (by Panel Type), $Million, 2020-2031

8.1 Overview
8.2 Single-Gene
8.3 Multi-Gene Panel

9 Global Lung Cancer Genomic Testing Market, (by Sample Type), $Million, 2020-2031

9.1 Overview
9.2 Tissue Biopsy
9.3 Liquid Biopsy
9.3.1 cfDNA
9.3.2 ctDNA

10 Global Lung Cancer Genomic Testing Market, (by End User), $Million, 2020-2031

10.1 Overview
10.2 Research Organization
10.3 Hospitals/Clinics
10.4 Diagnostic Laboratories
10.5 Other End Users

11 Global Lung Cancer Genomic Testing Market (by Region), $Million, 2020-2031

11.1 Overview
11.2 North America
11.2.1 North America: Market Dynamics
11.2.2 North America: Key Trends
11.2.3 U.S.
11.2.4 Canada
11.3 Latin America
11.3.1 Brazil
11.3.2 Mexico
11.3.3 Rest-of-Latin America (RoLA)
11.4 Europe
11.4.1 Europe: Market Dynamics
11.4.2 Europe: Key Trends
11.4.3 U.K.
11.4.4 Germany
11.4.5 Italy
11.4.6 Spain
11.4.7 France
11.4.8 Rest-of-Europe
11.5 Asia-Pacific
11.5.1 Asia-Pacific Lung Cancer Genomic Testing: Market Dynamics
11.5.2 Asia-Pacific: Key Trends
11.5.3 Japan
11.5.4 China
11.5.5 South-Korea
11.5.6 Singapore
11.5.7 Australia
11.5.8 India
11.5.9 Rest-of-Asia-Pacific
11.6 Rest-of-the-World
11.6.1 Key Trends in Rest-of-the-World Lung Cancer Genomic Testing Market

12 Company Profiles

12.1 Overview
12.2 QIAGEN N.V.
12.2.1 Company Overview
12.2.2 Role of QIAGEN N.V. in the Global Lung Cancer Genomic Testing Market
12.2.3 Key Competitors
12.2.4 Key Customers
12.2.5 Financials
12.2.5.1 Key Insights About Financial Health of the Company
12.2.6 Corporate Strategies
12.2.6.1 Mergers and Acquisitions
12.2.6.2 Synergistic Activities
12.2.6.3 Business Expansion and Funding
12.2.6.4 Product Launches and Upgradation
12.2.7 SWOT Analysis
12.3 Agilent Technologies, Inc.
12.3.1 Company Overview
12.3.2 Role of Agilent Technologies, Inc. in the Global Lung Cancer Genomic Testing Market
12.3.3 Key Competitors
12.3.4 Key Customers
12.3.5 Financials
12.3.5.1 Key Insights About Financial Health of the Company
12.3.6 Corporate Strategies
12.3.6.1 Mergers and Acquisitions
12.3.6.2 Synergistic Activities
12.3.6.3 Business Expansion and Funding
12.3.6.4 Product Launches and Upgradation
12.3.7 SWOT Analysis
12.4 Thermo Fisher Scientific, Inc.
12.4.1 Company Overview
12.4.2 Role of Thermo Fisher Scientific, Inc. in the Global Lung Cancer Genomic Testing Market
12.4.3 Key Competitors
12.4.4 Key Customers
12.4.5 Financials
12.4.5.1 Key Insights About Financial Health of the Company
12.4.6 Corporate Strategies
12.4.6.1 Mergers and Acquisitions
12.4.6.2 Synergistic Activities
12.4.6.3 Business Expansion and Funding
12.4.6.4 Product Launches and Upgradation
12.4.7 SWOT Analysis
12.5 Quest Diagnostics Incorporated
12.5.1 Company Overview
12.5.2 Role of Quest Diagnostics Incorporated in the Global Lung Cancer Genomic Testing Market
12.5.3 Key Competitors
12.5.4 Key Customers
12.5.5 Financials
12.5.6 Corporate Strategies
12.5.6.1 Mergers and Acquisitions
12.5.6.2 Synergistic Activities
12.5.6.3 Business Expansion and Funding
12.5.6.4 Product Launches and Upgradation
12.5.7 SWOT Analysis
12.6 Laboratory Corporation of America Holdings
12.6.1 Company Overview
12.6.2 Role of Laboratory Corporation of America Holdings in the Global Lung Cancer Genomic Testing Market
12.6.3 Key Competitors
12.6.4 Key Customers
12.6.5 Financials
12.6.6 Corporate Strategies
12.6.6.1 Mergers and Acquisitions
12.6.6.2 Synergistic Activities
12.6.6.3 Business Expansion and Funding
12.6.6.4 Product Launches and Upgradation
12.6.7 SWOT Analysis
12.7 CENTOGENE N.V.
12.7.1 Company Overview
12.7.2 Role of CENTOGENE N.V. in the Global Lung Cancer Genomic Testing Market
12.7.3 Key Competitors
12.7.4 Key Customers
12.7.5 Financials
12.7.6 Key Insights About Financial Health of the Company
12.7.7 Corporate Strategies
12.7.7.1 Mergers and Acquisitions
12.7.7.2 Synergistic Activities
12.7.7.3 Business Expansion and Funding
12.7.7.4 Product Launches and Upgradation
12.7.8 SWOT Analysis
12.8 BGI
12.8.1 Company Overview
12.8.2 Role of BGI in the Global Lung Cancer Genomic Testing Market
12.8.3 Key Competitors
12.8.4 Key Customers
12.8.5 Corporate Strategies
12.8.5.1 Mergers and Acquisitions
12.8.5.2 Synergistic Activities
12.8.5.3 Business Expansion and Funding
12.8.5.4 Product Launches and Upgradation
12.8.6 SWOT Analysis
12.9 CeGaT GmbH
12.9.1 Company Overview
12.9.2 Role of CeGaT GmbH in the Global Lung Cancer Genomic Testing Market
12.9.3 Key Competitors
12.9.4 Key Customers
12.9.5 Corporate Strategies
12.9.5.1 Mergers and Acquisitions
12.9.5.2 Synergistic Activities
12.9.5.3 Business Expansion and Funding
12.9.5.4 Product Launches and Upgradation
12.9.6 SWOT Analysis
12.1 Illumina, Inc.
12.10.1 Company Overview
12.10.2 Role of Illumina, Inc. in the Global Lung Cancer Genomic Market
12.10.3 Key Competitors
12.10.4 Key Customers
12.10.5 Financials
12.10.5.1 Key Insights About Financial Health of the Company
12.10.6 Corporate Strategies
12.10.6.1 Mergers and Acquisitions
12.10.6.2 Synergistic Activities
12.10.6.3 Business Expansion and Funding
12.10.6.4 Product Launches and Upgradation
12.10.7 SWOT Analysis
12.11 F. Hoffmann-La Roche Ltd.
12.11.1 Company Overview
12.11.2 Role of F. Hoffmann-La Roche Ltd. in the Global Lung Cancer Genomic Testing Market
12.11.3 Key Competitors
12.11.4 Key Customers
12.11.5 Financials
12.11.6 Key Insights About Financial Health of the Company
12.11.7 Corporate Strategies
12.11.7.1 Mergers and Acquisitions
12.11.7.2 Synergistic Activities
12.11.7.3 Business Expansion and Funding
12.11.7.4 Product Launches and Upgradation
12.11.8 SWOT Analysis
12.12 Abbott Laboratories
12.12.1 Company Overview
12.12.2 Role of Abbott Laboratories in the Global Lung Genomic Testing Market
12.12.3 Key Competitors
12.12.4 Key Customers
12.12.5 Financials
12.12.6 Key Insights About Financial Health of the Company
12.12.7 Corporate Strategies
12.12.7.1 Mergers and Acquisitions
12.12.7.2 Synergistic Activities
12.12.7.3 Business Expansion and Funding
12.12.7.4 Product Launches and Upgradation
12.12.8 SWOT Analysis
12.13 CD Genomics
12.13.1 Company Overview
12.13.2 Role of CD Genomics in the Global Lung Cancer Genomic Testing Market
12.13.3 Key Competitors
12.13.4 Key Customers
12.13.5 Corporate Strategies
12.13.5.1 Mergers and Acquisitions
12.13.5.2 Synergistic Activities
12.13.5.3 Business Expansion and Funding
12.13.5.4 Product Launches and Upgradation
12.13.6 SWOT Analysis
12.14 NeoGenomics Laboratories
12.14.1 Company Overview
12.14.2 Role of NeoGenomics Laboratories in the Global Lung Cancer Genomic Testing Market
12.14.3 Key Competitors
12.14.4 Key Customers
12.14.5 Financials
12.14.6 Key Developments
12.14.7 Key Insights About Financial Health of the Company
12.14.8 Corporate Strategies
12.14.8.1 Mergers and Acquisitions
12.14.8.2 Synergistic Activities
12.14.8.3 Business Expansion and Funding
12.14.8.4 Product Launches and Upgradation
12.14.9 SWOT Analysis
12.15 Admera Health
12.15.1 Company Overview
12.15.2 Role of Admera Health in the Global Lung Cancer Genomic Testing Market
12.15.3 Key Competitors
12.15.4 Key Customers
12.15.5 Corporate Strategies
12.15.5.1 Mergers and Acquisitions
12.15.5.2 Synergistic Activities
12.15.5.3 Business Expansion and Funding
12.15.5.4 Product Launches and Upgradation
12.15.6 SWOT Analysis
12.16 OncoDNA
12.16.1 Company Overview
12.16.2 Role of OncoDNA in the Global Lung Cancer Genomic Testing Market
12.16.3 Key Competitors
12.16.4 Key Customers
12.16.5 Corporate Strategies
12.16.5.1 Mergers and Acquisitions
12.16.5.2 Synergistic Activities
12.16.5.3 Business Expansion and Funding
12.16.5.4 Product Launches and Upgradation
12.16.6 SWOT Analysis
12.17 OPKO Health, Inc.
12.17.1 Company Overview
12.17.2 Role of OPKO Health, Inc. in the Global Lung Cancer Genomic Testing Market
12.17.3 Key Competitors
12.17.4 Key Customers
12.17.5 Financials
12.17.6 Key Insights About Financial Health of the Company
12.17.7 Corporate Strategies
12.17.7.1 Mergers and Acquisitions
12.17.7.2 Synergistic Activities
12.17.7.3 Business Expansion and Funding
12.17.7.4 Product Launches and Upgradation
12.17.8 SWOT Analysis
12.18 Emerging Companies
12.18.1 Invitae Corporation
12.18.1.1 Company Overview
12.18.1.2 Role of Invitae Corporation in the Global Lung Cancer Genomic Testing Market
12.18.1.3 Key Competitors
12.18.1.4 Key Customers
12.18.1.5 Financials
12.18.1.6 Key Insights About Financial Health of the Company
12.18.1.7 Corporate Strategies
12.18.1.7.1 Mergers and Acquisitions
12.18.1.7.2 Product Launches and Upgradation
12.18.1.8 SWOT Analysis
12.18.2 Veracyte, Inc.
12.18.2.1 Company Overview
12.18.2.2 Role of Veracyte, Inc. in the Global Lung Cancer Genomic Testing Market
12.18.2.3 Key Competitors
12.18.2.4 Key Customers
12.18.2.5 Financials
12.18.2.6 Key Insights About Financial Health of the Company
12.18.2.7 Corporate Strategies
12.18.2.7.1 Mergers and Acquisitions
12.18.2.7.2 Product Launches and Upgradation
12.18.2.8 SWOT Analysis

List of Figures

Figure 1: Types of Lung Cancer
Figure 2: Incidence and Mortality of Lung Cancer (in Thousands), 2018 and 2020
Figure 3: Global Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 4: Global Lung Cancer Genomic Testing Market, Market Dynamics
Figure 5: Share of Key Developments and Strategies, January 2017-February 2022
Figure 6: Global Lung Cancer Genomic Testing Market (by Product Type), $Million, 2020 vs. 2031
Figure 7: Global Lung Cancer Genomic Testing Market (by Technology), $Million, 2020 vs. 2031
Figure 8: Global Lung Cancer Genomic Testing Market (by Sample Type), $Million, 2020 vs. 2031
Figure 9: Global Lung Cancer Genomic Testing Market (by Panel Type), $Million, 2020 vs. 2031
Figure 10: Global Lung Cancer Genomic Testing Market (by End User), $Million, 2020 vs. 2031
Figure 11: Global Lung Cancer Genomic Testing Market (by Region), $Million, 2020 vs. 2031
Figure 12: Global Lung Cancer Genomic Testing Market: Segmentation
Figure 14: Primary Research Methodology
Figure 15: Bottom-Up Approach (Segment-Wise Analysis)
Figure 16: Top-Down Approach (Segment-Wise Analysis)
Figure 17: Global Five-Year Prevalence of Lung Cancer, 2015-2020 (in Thousands)
Figure 18: Global Lung Cancer Genomics Testing Market: COVID-19 Impact Analysis
Figure 19: COVID-19 Impact (March-June 2020)
Figure 20: Biomarker Testing Reduction in the U.S.: February-March 2020
Figure 21: Recommendations to Navigate COVID-19 Crisis
Figure 22: FDA Guidelines for Companion Diagnostics Approval
Figure 23: Criteria for CMS Coverage/Reimbursement
Figure 24: Components Considered for Clinical Actionability as per the In-Vitro Diagnostic Medical Devices Regulation
Figure 25: Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
Figure 26: China NMPA Regulatory Approval Process
Figure 27: Steps to Register a Medical Device in Japan
Figure 28: Regulatory Approval for Medical Devices in Latin-America
Figure 29: Country-Wise Analysis (January 2019-January 2022) of Patents Related to Lung Cancer Genomic Testing
Figure 30: Technology Wise Analysis (January 2019-January 2022) of Patents Related to Lung Cancer Genomic Testing
Figure 31: Market Dynamics
Figure 32: Likert Scale
Figure 33: Impact Analysis
Figure 34: Global Cancer Incidence (2020)
Figure 35: Global Cancer Mortality (2020)
Figure 36: Estimated Lung Cancer New Cases and Death in the U.S. in 2030 (in Thousands)
Figure 37: Cost of Genome Sequencing (2014-2021)
Figure 38: In-Vitro Diagnostics and Laboratory Developed Test Regulatory in the U.S., Europe, and Japan
Figure 39: Reimbursement Barriers in U.S., Europe, and APAC regions
Figure 40: ASCO Non-Small Cell Lung Cancer Biomarker Test Recommendations
Figure 41: ESMO Recommendations as per ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) Level for NGS Panel Test
Figure 42: Pan-Asia NSCLC Clinical Recommendations
Figure 43: Number of Cancer Research Funders Globally
Figure 44: Share of Key Developments and Strategies, January 2017-February 2022
Figure 45: Synergistic Activities Share (by Company), January 2017-January 2022
Figure 46: Product and Regulatory Approvals (by Company), January 2017-January 2022
Figure 47: Product Launches and Upgradations (by Company), January 2017–February 2022
Figure 48: Share of Acquisitions (by Company), January 2017-February 2022
Figure 49: Share of Business Expansion (by Company), January 2017-February 2022
Figure 50: Market Share Analysis for Global Lung Cancer Genomics Testing Market, $Million, 2019 and 2020
Figure 51: Growth-Share Analysis of Global Lung Cancer Genomics Testing Market (by Company) 2019-2020
Figure 52: Global Lung Cancer Genomic Testing Market (by Product Type)
Figure 53: Global Lung Cancer Genomic Testing Market (by Product Type), 2020 and 2031
Figure 54: Global Lung Cancer Genomic Testing Market (by Product Type), $Million, 2020-2031
Figure 55: Global Lung Cancer Genomic Testing Market (Services), $Million, 2020-2031
Figure 56: Global Lung Cancer Genomic Testing Market (Technology), 2020 and 2031
Figure 57: Global Lung Cancer Genomic Testing Market (Next-Generation Sequencing), $Million, 2020-2031
Figure 58: Global Lung Cancer Genomic Testing Market (Polymerase Chain Reaction), $Million, 2020-2031
Figure 59: Global Lung Cancer Genomic Testing Market (Fluorescence In-Situ Hybridization), $Million, 2020-2031
Figure 60: Global Lung Cancer Genomic Testing Market (Other), $Million, 2020-2031
Figure 61: Global Lung Cancer Genomic Testing Market (by Panel Type), 2020 and 2031
Figure 62: Global Lung Cancer Genomic Testing Market (Single-Gene Panel Type), $Million, 2020-2031
Figure 63: Global Lung Cancer Genomic Testing Market (Multi-Gene Panel Type), $Million, 2020-2031
Figure 64: Global Lung Cancer Genomic Testing Market (by Sample Type), $Million, 2020 and 2031
Figure 65: Global Lung Cancer Genomic Testing Market (Tissue Biopsy), $Million, 2020-2031
Figure 66: Global Lung Cancer Genomic Testing Market (Liquid Biopsy), $Million, 2020-2031
Figure 67: Global Lung Cancer Genomic Testing Market (Liquid Biopsy), $Million, 2020-2031
Figure 68: Global Lung Cancer Genomic Testing Market (cfDNA), $Million, 2020-2031
Figure 69: Global Lung Cancer Genomic Testing Market (ctDNA), $Million, 2020-2031
Figure 71: Global Lung Cancer Genomic Testing Market (by End User), $Million, 2020 and 2031
Figure 72: Global Lung Cancer Genomic Testing Market (Research Organization), $Million, 2020-2031
Figure 73: Global Lung Cancer Genomic Testing Market (Hospitals/Clinics), $Million, 2020-2031
Figure 74: Global Lung Cancer Genomic Testing Market (Diagnostic Laboratories), $Million, 2020-2031
Figure 75: Global Lung Cancer Genomic Testing Market (Other End Users), $Million, 2020-2031
Figure 76: Market Share of North America Lung Cancer Genomic Testing Market Revenue (by Country), $Million, 2020 and 2031
Figure 77: North America: Market Dynamics
Figure 78: North America: Key Trends
Figure 79: U.S. Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 80: Estimated Lung Cancer Cases in the U.S. (in Thousands), 2018-2022
Figure 81: Canada Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 82: Latin America Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 83: Latin America: Market Dynamics
Figure 84: Market Share of Latin America Lung Cancer Genomic Testing Market Revenue (by Country), $Million, 2020 and 2031
Figure 85: Brazil Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 86: Mexico Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 87: Rest-of-Latin America (RoLA) Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 88: Market Share of Europe Lung Cancer Genomic Testing Market Revenue (by Country), $Million, 2020 and 2031
Figure 89: Europe: Market Dynamics
Figure 90: Europe: Key Trends
Figure 91: U.K. Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 92: Germany: Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 93: Italy Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 94: Spain Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 95: France Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 96: Rest-of-Europe Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 97: Asia-Pacific Lung Cancer Genomic Testing Market (by Country), $Million, 2020 and 2031
Figure 98: Japan Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 99: China Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 100: South-Korea Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 101: Singapore Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 102: Australia Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 103: India Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 104: Rest-of-Asia-Pacific Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 105: Rest-of-the-World Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 106: Total Number of Companies Profiled
Figure 107: QIAGEN N.V.: Product Portfolio
Figure 108: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 109: QIAGEN N.V.: Revenue (by Business Segment), 2018-2020
Figure 110: QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 111: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 112: QIAGEN N.V.: SWOT Analysis
Figure 113: Agilent Technologies, Inc.: Product Portfolio
Figure 114: Agilent Technologies, Inc.: Overall Financials, 2018-2021
Figure 115: Agilent Technologies, Inc.: Revenue (by Business Segment), 2018–2021
Figure 116: Agilent Technologies, Inc.: Revenue (by Product Type), 2018–2021
Figure 117: Agilent Technologies, Inc.: Revenue (by Region), 2019-2021
Figure 118: Agilent Technologies, Inc.: R&D Expenditure, 2018-2021
Figure 119: Agilent Technologies, Inc.: SWOT Analysis
Figure 120: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 121: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2021
Figure 122: Thermo Fisher Scientific, Inc.: Revenue (by Business Segment), 2018–2020
Figure 123: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2018–2020
Figure 124: Thermo Fisher Scientific, Inc.: R&D Expenditure, 2018-2020
Figure 125: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 126: Quest Diagnostics Incorporated.: Product Portfolio
Figure 127: Quest Diagnostics: Overall Financials, 2018-2021
Figure 128: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2018–2021
Figure 129: Quest Diagnostics Incorporated: SWOT Analysis
Figure 130: Laboratory Corporation of America Holdings: Product Portfolio
Figure 131: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 132: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 133: Laboratory Corporation of America Holdings: Revenue (by Region), 2018-2020
Figure 134: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 135: CENTOGENE N.V.: Product Portfolio
Figure 136: CENTOGENE N.V.: Overall Financials, 2018-2020
Figure 137: CENTOGENE N.V.: Revenue (by Business Segment), 2018–2020
Figure 138: CENTOGENE N.V.: Revenue (by Region), 2018-2020
Figure 139: CENTOGENE N.V.: R&D Expenditure, 2018-2020
Figure 140: CENTOGENE N.V.: SWOT Analysis
Figure 141: BGI: Product Portfolio
Figure 142: BGI: SWOT Analysis
Figure 143: CeGaT GmbH: Product Portfolio
Figure 144: CeGaT GmbH: SWOT Analysis
Figure 145: Illumina, Inc.: Product Portfolio
Figure 146: Illumina, Inc.: Overall Financials, 2018-2021
Figure 147: Illumina, Inc.: Revenue (by Business Segment), 2018–2020
Figure 148: Illumina, Inc.: Revenue (by Business Segment, by Technology), 2018–2020
Figure 149: Illumina, Inc.: Revenue (by Region), 2018–2020
Figure 150: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 151: Illumina, Inc.: SWOT Analysis
Figure 152: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 153: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2021
Figure 154: F. Hoffmann-La Roche Ltd.: Revenue (by Business Segment), 2018–2021
Figure 155: Hoffmann-La Roche Ltd.: Revenue (by Region), 2018–2020
Figure 156: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
Figure 157: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 158: Abbott Laboratories: Product Portfolio
Figure 159: Abbott Laboratories: Overall Financials, 2018-2020
Figure 160: Abbott Laboratories: Revenue (by Segment), 2018-2021
Figure 161: Abbott Laboratories: Revenue (by Region), 2018-2020
Figure 162: Abbott Laboratories: R&D Expenditure, 2018-2020
Figure 163: Abbott Laboratories: SWOT Analysis
Figure 164: CD Genomics: Product Portfolio
Figure 165: CD Genomics: SWOT Analysis
Figure 166: NeoGenomics Laboratories: Product Portfolio
Figure 167: NeoGenomics Laboratories: Overall Financials, 2018-2021
Figure 168: NeoGenomics Laboratories: Revenue (by Business Segment), 2018–2021
Figure 169: NeoGenomics Laboratories: R&D Expenditure, 2018-2021
Figure 170: NeoGenomics Laboratories: SWOT Analysis
Figure 171: Admera Health: Product Portfolio
Figure 172: Admera Health: SWOT Analysis
Figure 173: OncoDNA: Product Portfolio
Figure 174: OncoDNA: SWOT Analysis
Figure 175: OPKO Health, Inc.: Product Portfolio
Figure 176: OPKO Health, Inc.: Overall Financials, 2018-2021
Figure 177: OPKO Health, Inc.: Revenue (by Region), 2018-2020
Figure 178: OPKO Health, Inc.: Revenue (by Business Segment), 2018–2021
Figure 179: OPKO Health, Inc.: R&D Expenditure, 2018-2021
Figure 180: OPKO Health, Inc.: SWOT Analysis
Figure 181: Invitae Corporation: Product Portfolio
Figure 182: Invitae Corporation: Overall Financials, 2018-2021
Figure 183: Invitae Corporation: Revenue (by Business Segment), 2018–2021
Figure 184: Invitae Corporation: R&D Expenditure, 2018-2021
Figure 185: Invitae Corporation: SWOT Analysis
Figure 186: Veracyte, Inc.: Product Portfolio
Figure 187: Veracyte, Inc.: Overall Financials, 2018-2021, $Million
Figure 188: Veracyte, Inc.: Revenue (by Business Segment), 2018–2021
Figure 189: Veracyte, Inc.: Revenue (by Region), 2018-2021
Figure 190: Veracyte, Inc.: R&D Expenditure, 2018-2021
Figure 191: Veracyte, Inc.: SWOT Analysis

List of Tables

Table 1: Priority Genetic Testing at Diagnosis for Advanced Non-Squamous Non-Small Cell Lung Cancer
Table 2: Classification of Medical Device
Table 3: Lung Cancer Genetic Mutation and Targeted Therapies
Table 4: Companies Providing Kits and Assays
Table 5: Companies Offering Services
Table 6: FDA Approved Lung Cancer NGS Assays
Table 7: Lung Cancer Insights in 2018
Table 8: Hoffmann-La Roche Ltd.: Revenue for Tissue Diagnostics Segment

Companies Mentioned

QIAGEN N.V.
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
CENTOGENE N.V.
BGI
CeGaT GmbH
Illumina, Inc.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
CD Genomics
NeoGenomics Laboratories
Admera Health
OncoDNA
OPKO Health, Inc.
Invitae Corporation
Veracyte, Inc.

Table Information

Report Attribute	Details
No. of Pages	244
Published	May 2022
Forecast Period	2021 - 2031
Estimated Market Value ( USD ) in 2021	$ 1389.5 Million
Forecasted Market Value ( USD ) by 2031	$ 3279.8 Million
Compound Annual Growth Rate	9.0%
Regions Covered	Global
No. of Companies Mentioned	18

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€5077EUR$5,250USD£4,300GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€7833EUR$8,100USD£6,634GBP